UroGen Pharma (URGN) shares tumbled 48% in recent Wednesday trading after the company said its UGN-102 bladder cancer drug failed to receive the backing of a US Food and Drug Administration advisory committee.
The new drug application for UGN-102 is currently under review by the FDA with a decision expected on June 13, the company said Wednesday in a statement.
"While we are disappointed by today's outcome, we continue to believe our clinical data support UGN-102 for the treatment of recurrent LG-IR-NMIBC, a disease with no FDA-approved therapies," UroGen Pharma Chief Executive Officer Liz Barrett said in the statement.
"The FDA carefully considers the independent advice" from the Oncologic Drugs Advisory Committee, and "we look forward to working with the FDA as they complete their review of the application for UGN-102," Barrett said.
UGN-102, or mitomycin, is designed to treat recurrent low-grade intermediate-risk non-muscle invasive bladder cancer.
Price: 3.91, Change: -3.63, Percent Change: -48.14
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。